Argitalpenak (44) Sara Labiano Almiñana argitalpenak

2024

  1. Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry

    STAR Protocols, Vol. 5, Núm. 1

  2. Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models

    JCI Insight, Vol. 9, Núm. 18

  3. Radiotherapy protocols for mouse cancer model

    Methods in Cell Biology (Academic Press Inc.), pp. 99-113

  4. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

    Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525

2023

  1. Flow cytometry-assisted quantification of immune cells infiltrating irradiated tumors in mice

    Methods in Cell Biology, Vol. 174, pp. 1-16

  2. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2022

  1. Assessment of hypoxia by pimonidazole staining following radiotherapy

    Methods in Cell Biology (Academic Press Inc.), pp. 179-189

  2. Editorial: The Impact of Angiogenic Growth Factors and Hypoxia on the Antitumor Immune Response

    Frontiers in Immunology

  3. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas

    JCI Insight, Vol. 7, Núm. 7

  4. Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 26, pp. 246-264

  5. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory

    Molecular Cancer Therapeutics, Vol. 21, Núm. 3, pp. 471-480

  6. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

2021

  1. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 7

  2. CD40 agonist targeted to fibroblast activation protein a synergizes with radiotherapy in murine HPV-positive head and neck tumors

    Clinical Cancer Research, Vol. 27, Núm. 14, pp. 4054-4065

  3. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

    Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820

  4. Erratum: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models (Journal for ImmunoTherapy of Cancer (2021) 9 (e002644) DOI: 10.1136/jitc-2021-002644)

    Journal for ImmunoTherapy of Cancer

  5. Fibroblast activation protein a-targeted CD40 agonism abrogates systemic toxicity and enables administration of high doses to induce effective antitumor immunity

    Clinical Cancer Research, Vol. 27, Núm. 14, pp. 4036-4053

  6. Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 20, pp. 23-33

2020

  1. Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells

    Frontiers in Immunology, Vol. 11

2019

  1. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

    Cancer cell, Vol. 36, Núm. 6, pp. 613-629